Dry Eye Syndromes Clinical Trial
Official title:
Comparison Between Rebamipide 2% Versus Autologous Serum in the Treatement of the Moderate to Severe Dry Eye Associate With Sjögren Syndrome. Pilot, Crossed, Controled, Randomized And Open Study
Two-period, controlled, randomized and open clinical trial. The sample was composed of adult women with moderate to severe hypo secretory dry eye associated with Sjögren's syndrome, who attended the ocular surface office, derived from the general ophthalmology clinic, from the Rheumatology or Immunology department. The three interventions were randomized: autologous serum (GSA), Rebamipida 2% (GR) and a combined treatment (GSAR). The following were used as outcome measures: OSDI self-administered questionnaire (Ocular Surface Disease Index), tear-rupture time (BUT), fluorescein staining, Bengal Rose staining and Schirmer's test without anesthesia to assess the answer to each treatment
After having borrowed to participate in the study, we proceeded to the random assignment of
each intervention as follow: the last 2 numbers of the clinical history, typical of the
ocular surface office, were taken and they were placed in a list in order of lower to higher.
Then, each of them was assigned to a number from a table of random numbers. The list was
rearranged from lowest to highest using the assigned random number. Finally, the treatment
was assigned by simple randomization without replacement. In this way, the subject with the
lowest random number, the correspondence in the first treatment drawn. It was continued in
the same way, respecting the order assigned by random numbers until completing the 21
subjects.
Three groups of 7 subjects each were formed in this way: treatment group or group Rebamipida
(GR); standard treatment group or autologous serum group (GSA) and mixed group or serum and
Rebamipide group (GSAR).
Before beginning with the assigned treatment, all the participants was started a period of
wash-out of any medicine they were ussing, that least for two weeks. The participants were
asked to suspend all the drops that they been used until then (antibiotics, corticosteroids,
cyclosporine, artificial tears, autologous serum, etc.), and to place them using only
artificial tears (sodium carboxymethyl cellulose). 1%, AUCIC 1%) four times a day in all
cases. The purpose was to minimize the effect of the medication that could interfere with the
results obtained from the treatments tested. The two week period also allowed the hemotherapy
service to prepare the autologous serum for the subjects assigned to this group and initiate
the treatment without delays.
Immediately after the washout period, the subjects began to receive the last treatments for
90 days.
After the first intervention cycle and with the objective of influencing the treatment cycle
of the first treatment cycle, a second washing period of two weeks duration was carried out.
With the intention of increasing the sample size, the GR and GSA groups were crossed, in this
way the patients received the opposite treatment to the start. The second treatment period
lasted 90 days, equal to the first.
The mixed group (GSAR) did not cross, ending their participation at the end of the 90 days.
Admission and control of all patients on days 0, 30 and 90 of both cycles were performed by
the same ophthalmologist.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04425551 -
Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction
|
N/A | |
Not yet recruiting |
NCT06379685 -
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
|
Phase 1 | |
Recruiting |
NCT04701086 -
3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis
|
N/A | |
Active, not recruiting |
NCT03697876 -
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
|
Phase 1 | |
Completed |
NCT02910713 -
Evaluation of Dry Eye Symptoms in CAE With Application of Intranasal Neurostimulation
|
N/A | |
Terminated |
NCT02815293 -
Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT04104997 -
A Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of GLH8NDE After Single and Mutiple Ocular Administrations in Healthy Korean and Caucasian Volunteers
|
Phase 1 | |
Recruiting |
NCT02595606 -
0.3% Sodium Hyaluronate in the Treatment of Dry Eye of Diabetic Patients
|
Phase 4 | |
Completed |
NCT01711424 -
An Observational Study of OPTIVE PLUS® for the Treatment of Dry Eye Disease
|
N/A | |
Completed |
NCT01202747 -
Evaluation of Screening Methods for Treatment of Meibomian Gland Dysfunction
|
Phase 2/Phase 3 | |
Completed |
NCT01015209 -
Safety and Tolerability of Chitosan-N-acetylcysteine Eye Drops in Healthy Young Volunteers
|
Phase 1 | |
Completed |
NCT00969280 -
Acupuncture for Dry Eye Syndrome
|
Phase 3 | |
Completed |
NCT01496482 -
Comparison of Evaporimetry With the Established Methods of Tear Film Measurement
|
N/A | |
Completed |
NCT00739713 -
Effects of Sea Buckthorn Oil on Dry Eye
|
N/A | |
Completed |
NCT00756678 -
Efficacy and Acceptability of Two Lubricant Eye Drops
|
Phase 4 | |
Completed |
NCT00370747 -
Efficacy and Safety Study for Ecabet Ophthalmic Solution for Treating Dry Eye Syndrome
|
Phase 2 | |
Completed |
NCT00349440 -
Efficacy of Cyclosporine for the Prevention and Treatment of Dry Eye Symptoms Following LASIK or Photorefractive Keratectomy
|
Phase 4 | |
Completed |
NCT05162261 -
to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction
|
N/A | |
Completed |
NCT02871440 -
A Two Comparator, Controlled Phase 3 Study in Patients With and Without Evaporative Dry Eye
|
Phase 3 | |
Completed |
NCT05042960 -
Computer Screen Properties Study
|
N/A |